In Butterfield study, which was funded by the National Institutes of Health, he focused on beta-amyloid peptide, a compound known to contribute to the senile plaques seen in the brains of Alzheimer’s patients. The study compared found amyloid beta peptide in an animal model to the same compound in humans and both forms of the compound caused a loss of the connections between the neurons and reduced viability of the cells as well as other damage associated with Alzheimer’s.
TG 101348 Besides preclinical compound topically applied.y has two other internally discovered drugs in human clinical trials. These include TG100-115, which evaluated in patients with myocardial infarction and TG100801, a topically applied. potential therapy for macular degeneration and other eye diseases TG100801 is currently in Phase I clinical trials.To on AAKP that is Speakers Bureau extremely rewarding , the way in which one patient or a family member for Her story empowered Share with other other patients, ‘said Kris Robinson, AAKP Executive Director of / Chief Executive.. American Association of Kidney Patients Searches people to his Speakers Bureau in 2007 Annual Convention ServeRAID.
Addition patients and healthcare professionals look AAKP are members of their family and caregivers who are interesting to to experiences with respect in a loved one with kidney disease. Normal, views and evidence serve as an ideal entry point for panel discussion.